BSC SYMPOSIUM
SAVE THE DATE
Our annual symposium will be held on Saturday, December 7, 2024
This year’s symposium will focus on the interaction between lipid as well as management of small vessel disease.
Registration is now open!
BSC statement regarding the use of TNK for treatment of acute ischemic stroke
The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.
Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.
For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.
BSC opinion statement in dutch
Prevent, Treat and Support: a manifesto for stroke survivors
The Stroke Alliance for Stroke ( SAFE) and the European Stroke Organisation (ESO) have published a manifesto outlining a number of keypoints to improve prevention, treatment and support for stroke patients across Europe. In the meantime, a letter has been sent to all Belgian members of the European Parliament and Belgian ministers of health, asking them to consider including these initiatives in their electoral programs. Read the manifesto here and the letter sent to our ministers here
BSC Applauds Initial Step in Stroke Care Structuring but Calls for Uniform Criteria Across Regions
On 23 May 2024, the BSC published a press release applauding the recognition of Belgian S2 centres, but calling for uniform certification criteria across the country. Read it here
Update on Alteplase and Tenecteplase shortage – ESO Statement and Information
On April 14, the ESO published their 4th information letter about alteplase and tenecteplase shortage in Europe.